Ambrisentan

Drug Profile

Ambrisentan

Alternative Names: BSF 208075; GSK 1325760; GSK1325760A; Letairis; Volibris

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Abbott GmbH & Co. KG
  • Developer Gilead Sciences; GlaxoSmithKline
  • Class Phenylpropionates; Pyridazines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Pulmonary hypertension
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary hypertension
  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 25 Nov 2015 Registered for Pulmonary hypertension (Combination therapy, First-line therapy) in European Union (PO)
  • 25 Nov 2015 Registered for Pulmonary hypertension (Combination therapy, First-line therapy) in Norway, Iceland, Liechtenstein (PO)
  • 01 Nov 2015 GlaxoSmithKline completes a phase III trial in chronic thromboembolic Pulmonary hypertension in the US, Argentina, Austria, Canada, China, Czech Republic, Germany, Israel, Japan, Mexico, the Netherlands, Russia, Saudi Arabia, South Korea, Spain, and the United Kingdom (PO) (NCT01894022)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top